Harrow, Inc. - HROW STOCK NEWS

Harrow (HROW) announced a favorable jury verdict in a trademark infringement case where its subsidiary ImprimisRx sued OSRX, Inc. and Ocular Science, Inc. The eight-person jury unanimously found the defendants guilty of willful trademark infringement and unfair competition, awarding $34.9 million in damages. The verdict includes $20.4 million in punitive damages and $14.5 million in actual damages. The case was tried in the United States District Court for the Southern District of California, where the jury validated ImprimisRx's trademark estate and found the defendants acted with malice, fraud, or oppression.

Melt Pharmaceuticals announced positive Phase 3 topline results for MELT-300, a non-IV, non-opioid sublingual tablet for procedural sedation during cataract surgery. The study, involving over 530 patients across 13 U.S. clinical sites, demonstrated MELT-300's statistical superiority over both sublingual midazolam (P=0.009) and placebo (P<0.001). The tablet combines midazolam (3mg) and ketamine (50mg), dissolving in 3 seconds using Catalent's Zydis® technology. Patients receiving midazolam alone required nearly twice the rescue sedation compared to MELT-300 (P=0.003), while MELT-300 showed a favorable safety profile comparable to placebo.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in three upcoming investor conferences. The company will attend the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, the BTIG 4th Annual Ophthalmology Day on December 2, 2024, and the Piper Sandler 36th Annual Healthcare Conference from December 3-5, 2024.

Management will conduct one-on-one meetings at all conferences. A Fireside Chat is scheduled for December 4, 2024, at 8:00 a.m. ET during the Piper Sandler conference, which will be the only event featuring an audio webcast available on Harrow's website.

Harrow (HROW) reported strong Q3 2024 results with revenues increasing 44% year-over-year to $49.3 million. The company posted a GAAP net loss of $(4.2) million and Adjusted EBITDA of $8.8 million. Key highlights include a 55% increase in VEVYE prescriptions over Q2 2024, 15% growth in IHEEZO customer unit demand, and operating cash flow of $3 million. The company maintained strong cash position with $72.6 million in cash and equivalents. Despite Q3 seasonal challenges, management expects Q4 revenue to meaningfully exceed 2024 guidance, driven by positive demand trends for VEVYE, IHEEZO, and TRIESENCE products.

Harrow (HROW) announced a new initiative to improve access and affordability of its ophthalmic pharmaceutical products through two main strategies. First, the company is implementing price reductions for several products, starting with VIGAMOX® and MAXIDEX®. Second, Harrow established a partnership with GoodRx to provide discounted pricing for seven products including FLAREX®, ILEVRO®, MAXIDEX®, TOBRADEX® ST, VEVYE®, VIGAMOX®, and ZERVIATE® through GoodRx's platform, particularly benefiting uninsured and underinsured patients.

Harrow (HROW) has secured significant market access for VEVYE in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in formularies managed by Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, reaching over 25 million Medicare Part D beneficiaries. The drug has achieved coverage across 100% of U.S. Medicaid programs and 60% of commercial insurance coverage. This expansion particularly benefits older adults among the 67 million Medicare beneficiaries, including 54 million with Part D coverage, who are at increased risk for chronic dry eye disease (DED).

Harrow (HROW) has announced a nationwide launch of a digital patient access solution in partnership with Asembia, aiming to expand access to Harrow's ophthalmic branded products. The collaboration leverages ASPN Pharmacies, Asembia's non-dispensing pharmacy, to streamline prescription processes and improve medication accessibility and affordability. The service includes benefits verification, prior authorization, co-pay support, and patient assistance program eligibility. Healthcare providers can order through their EHR/EMR platforms or the ASPN provider portal, which allows multiple Harrow products to be ordered simultaneously.

Harrow (Nasdaq: HROW), a North American eyecare pharmaceutical company, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, after market close. The company will publish its quarterly Letter to Stockholders on its website and host a conference call with a business update on November 14, 2024, at 8:00 a.m. Eastern Time. Interested participants can join via webcast through Harrow's website or by telephone after registering in advance.

Melt Pharmaceuticals has announced the completion of patient dosing in its pivotal Phase 3 study for MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The study, conducted at 13 clinical sites with over 525 patients, compares MELT-300 to sublingual midazolam and placebo. Topline results are expected by the end of 2024.

The FDA has agreed to a Special Protocol Assessment (SPA) for the MELT-300 Phase 3 study, establishing a binding agreement on key elements for a future marketing application. Additionally, a cardiac safety study showed MELT-300 does not alter normal heart rhythm.

MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in a sublingual tablet using Catalent's Zydis® delivery technology. Previous Phase 2 results showed MELT-300 was statistically superior for procedural sedation compared to placebo, midazolam, and ketamine individually.